Final Program

SATURDAY • MAY 14 17
• to diagnose active NTM infection;
• understand the pathophysiology and impact of exposure to the water supply
with regards to NTM infection;
• appropriately refer more complex NTM patients to centers worldwide with
special competence in NTM infections.
This postgraduate course includes a state of the art update on non tuberculous
mycobacterial lung disease with an emphasis on case based learning to
understand the prevalence, pathophysiology, treatment strategies and
controversies about the disease.
Chairing: A. O’Donnell, MD, Washington, DC
R. Thomson, MBBS, PhD, Brisbane, Australia
8:00 Why Are We Seeing an Increase in NTM Lung Disease?
K.N. Olivier, MD, MPH, Bethesda, MD
8:50 Does Exposure to Potable Water Cause NTM Infection?
R. Thomson, MBBS, PhD, Brisbane, Australia
9:30 NTM Identification: What Your Clinical Lab Needs to Tell You
A. O’Donnell, MD, Washington, DC
10:00 Break
10:15 NTM Has Been Isolated: Does the Patient Need Antibiotics?
T.R. Aksamit, MD, Rochester, MN
10:55 Antibiotic Treatment for MAC Lung Infection
K. Winthrop, MD, MPH, Portland, OR
11:45 LUNCH
12:45 M. Abscessus Lung Infection Antibiotic Treatment
T.K. Marras, MD, Toronto, Canada
1:35 Old Drugs for Old Bugs
J. Philley, MD, Tyler, TX
2:15 Break
2:30 Case Reviews
A. O’Donnell, MD, Washington, DC
A. Basavaraj, MD, New York, NY
3:30 ATS/ERS Updated NTM Guidelines/Panel Wrap Up
D.E. Griffith, MD, Tyler, TX
This session and the International Conference are supported by an educational grant from
Insmed Incorporated.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
PG19
CLINICAL • TRANSLATIONAL
POSTGRADUATE COURSE
CME Credits Available: 7.0
COPD: A DYNAMIC AND EVOLVING DISEASE
Pre-registration and additional fees required. Continental breakfast and
box lunch included. Attendance is limited.
Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300
Registrants must bring a laptop to the
course to view the course material.
Assemblies on Clinical Problems; Behavioral Science and Health
Services Research; Critical Care; Pulmonary Rehabilitation; Sleep and
Respiratory Neurobiology
8:00 a.m. - 4:00 p.m. MOSCONE CENTER
Room 2001 (West Building, Level 2)
Target Audience
Clinicians, nurses and respiratory therapistst; clinical and basic science
researchers; physicians in training and anybody who designs or implements
clinical trials in COPD.
Objectives
At the conclusion of this session, the participant will be able to:
• understand the many systemic comorbidities associated with COPD and
how to treat them;
• describe interventions to use for the management of COPD and COPD
exacerbations;
• describe how to use different medications in the treatment of COPD
patients.
This course will provide an update on key advances in the pathophysiology,
genetics and management of COPD patients. There have been extensive
publications on topics related to phenotype classification, use of imaging,
biomarker and early interventions in COPD. Furthermore, over the last year, there
have been numerous publications of novel bronchodilators that were approved by
different regulatory organizations including the FDA. COPD exacerbations
continue to impact the morbidity and mortality of this disease. There is a need to
address how this condition can be prevented and to discuss its treatment.
Chairing: G.J. Criner, MD, Philadelphia, PA
R. Casaburi, MD, PhD, Torrance, CA
8:00 What is the Status of COPD Today?
K.F. Rabe, MD, PhD, Grosshansdorf, Germany
8:15 How Can We Predict Disease Progression?
J. Soriano, MD, PhD, Madrid, Spain
8:45 What Are the COPD Phenotypes Relevant for Clinical Practice?
M. Miravitlles, MD, PhD, Barcelona, Spain
9:15 Accelerated Aging in COPD and Its Comorbidities: Pathways
to New Therapies
P.J. Barnes, MD, DSc, London, United Kingdom
9:45 Break
9:55 Integrating Disease Severity and Co-Morbid Conditions
C. Vogelmeier, MD, Marburg, Germany
10:25 How Can Radiological Imaging Change Our Concepts and
COPD Phenotypes?
G.R. Washko, MD, Boston, MA
10:55 The Association Between COPD and Cardiovascular Disease:
Mechanistic Links and Clinical Implications
D. Chandra, MD, MSc, Pittsburgh, PA
11:25 How is the COPD Biomarker Qualification Consortium Helping
Develop Treatments Targeted for COPD Subsets?
R. Tal-Singer, PhD, King of Prussia, PA
11:55 LUNCH
12:35 In What Patients Should I Use Fixed LABA-LAMA Combination?
A. Anzueto, MD, San Antonio, TX
SATURDAY
ATS 2016 • San Francisco